Cardiovascular disease (CVD) risk assessment of HIV medication regimens using hematopoietic CD34+ progenitor cells.
Adrian Farid ElzarkiSeshagiri Rao NandulaHassan AwalGary L SimonSabyasachi SenPublished in: Stem cell research & therapy (2022)
gov Identifier: NCT03782142.
Keyphrases
- risk assessment
- cardiovascular disease
- antiretroviral therapy
- hiv positive
- hiv infected
- hiv testing
- human immunodeficiency virus
- hepatitis c virus
- hiv aids
- human health
- bone marrow
- men who have sex with men
- heavy metals
- healthcare
- type diabetes
- adverse drug
- nk cells
- cardiovascular risk factors
- south africa
- emergency department
- metabolic syndrome
- climate change